Alex Mezei

Alex Mezei

Auto-generated profile, based on publicly available information

Alex Mezei

Department of Medicine, University of British Columbia, Vancouver, BC, Canada

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 April 2017 in International Journal of Cancer
Verified
Journal Article
Closed access
PDF file
AMAlex K. Mezei
Alex K. Mezei
HAHeather Armstrong
Heather Armstrong
HPHeather N. Pedersen
Heather N. Pedersen
NCNicole G. Campos
Nicole G. Campos
SMSheona M. Mitchell
Sheona M. Mitchell
GOGina Ogilvie
Gina Ogilvie

12 June 2018 in BMJ Open
Verified
Journal Article
Open access
PDF file
AMAlex K Mezei
Alex K Mezei
HPHeather N Pedersen
Heather N Pedersen
SSStephen Sy
Stephen Sy
CRCatherine Regan
Catherine Regan
SMSheona M Mitchell-Foster
Sheona M Mitchell-Foster
NCNicole G Campos
Nicole G Campos
Background Cervical cancer is the leading cause of cancer death for women in Uganda, despite the potential for prevention through organised screening. Community-based self-collected human papillomavirus (HPV) testing has been proposed to reduce barriers to screening. Objective Our objective was to evaluate the cost-effectiveness of the Advances in Screening and Prevention of Reproductive Cancers (ASPIRE) trial, conducted in Kisenyi, Uganda in April 2014 (n=500). The trial compared screening uptake and compliance with follow-up in two arms: (1) community-based (ie, home or workplace) self-collected HPV testing (facilitated by community health workers) with clinic-based visual inspection with acetic acid (VIA) triage of HPV-positive women (‘HPV-VIA’) and (2) clinic-based VIA (‘VIA’). In both arms, VIA was performed at the local health unit by midwives with VIA-positive women receiving immediate treatment with cryotherapy. Design We informed a Monte Carlo simulation model of HPV infection and cervical cancer with screening uptake, compliance and retrospective cost data from the ASPIRE trial; additional cost, test performance and treatment effectiveness data were drawn from observational studies. The model was used to assess the cost-effectiveness of each arm of ASPIRE, as well as an HPV screen-and-treat strategy (‘HPV-ST’) involving community-based self-collected HPV testing followed by treatment for all HPV-positive women at the clinic. Outcome measures The primary outcomes were reductions in cervical cancer risk and incremental cost-effectiveness ratios (ICERs), expressed in dollars per year of life saved (YLS). Results HPV-ST was the most effective and cost-effective screening strategy, reducing the lifetime absolute risk of cervical cancer from 4.2% (range: 3.8%–4.7%) to 3.5% (range: 3.2%–4%), 2.8% (range: 2.4%–3.1%) and 2.4% (range: 2.1%–2.7%) with ICERs of US$130 (US$110–US$150) per YLS, US$240 (US$210–US$280) per YLS, and US$470 (US$410–US$550) per YLS when performed one, three and five times per lifetime, respectively. Findings were robust across sensitivity analyses, unless HPV costs were more than quadrupled. Conclusions Community-based self-collected HPV testing followed by treatment for HPV-positive women has the potential to be an effective and cost-effective screening strategy.

1 May 2016 in Injury
Verified
Journal Article
Closed access
NONathan N. O’hAra
Nathan N. O’hAra
RMRodney Mugarura
Rodney Mugarura
JPJeffrey Potter
Jeffrey Potter
TSTrina Stephens
Trina Stephens
MRM. Marit Rehavi
M. Marit Rehavi
GSGerard P. Slobogean
Gerard P. Slobogean

1 June 2021 in Epidemics
Verified
Journal Article
Open access
AMAlex Mezei
Alex Mezei
JCJamie Cohen
Jamie Cohen
MRMatthew J. Renwick
Matthew J. Renwick
JAJessica Atwell
Jessica Atwell
Allison PortnoyAllison Portnoy
Allison Portnoy
Due to high burden of respiratory syncytial virus (RSV) in low- and middle-income countries (LMIC), international funding organizations have prioritized the development of RSV vaccines. Mathematical models of RSV will play an important role in assessing the relative value of these interventions. Our objectives were to provide an overview of the existing RSV modelling literature in LMIC and summarize available results on population-level effectiveness and cost-effectiveness. We searched MEDLINE from 2000 to 2020 for English language publications that employed a mathematical model of RSV calibrated to LMIC. Qualitative data were extracted on study and model characteristics. Quantitative data were collected on key model input assumptions and base case effectiveness and cost-effectiveness estimates for various immunization strategies. Of the 283 articles reviewed, 15 met inclusion criteria. Ten studies used modelling techniques to explore RSV transmission and/or natural history, while eight studies evaluated RSV vaccines and/or monoclonal antibodies, three of which included cost-effectiveness analyses. Six studies employed deterministic compartmental models, five studies employed individual transmission models, and four studies used different types of cohort models. Nearly every model was calibrated to at least one middle-income country, while four were calibrated to low-income countries. The mathematical modelling literature in LMIC has demonstrated the potential effectiveness of RSV vaccines and monoclonal antibodies. This review has demonstrated the importance of accounting for seasonality, social contact rates, immunity from prior infection and maternal antibody transfer. Future models should consider incorporating individual-level risk factors, subtype-specific effects, long-term sequelae of RSV infections, and out-of-hospital mortality.

1 February 2024 in JCO Global Oncology
Verified
Journal Article
Open access
AMAlex Mezei
Alex Mezei
JTJessica Trawin
Jessica Trawin
BPBeth Payne
Beth Payne
ARAngeli Rawat
Angeli Rawat
PNPriscilla Naguti
Priscilla Naguti
GOGina Ogilvie
Gina Ogilvie
PURPOSE: To assess the acceptability of integrated screening for cervical cancer and HIV in the community setting. METHODS: We developed surveys for patients and community health workers (CHWs) who participated in the Advances in Screening and Prevention in Reproductive Cancers (ASPIRE) Mayuge trial that compared self-collected human papillomavirus testing at home versus community health meetings in Mayuge district, Uganda. Quantitative data were summarized using descriptive statistics. Open-ended questions were analyzed using an inductive approach with thematic content analysis. RESULTS: We conducted 102 patient surveys and 31 CHW surveys between June and August 2021. Ninety-nine percent of patients and 100% of CHWs indicated that they would find the addition of an HIV test to their self-collected cervical cancer test acceptable. The most frequently stated reasons in favor of adding an HIV test to the ASPIRE Mayuge cervical cancer screening pathways were time-saving, privacy, and support from other women and CHWs. The most frequently stated reasons against integrated screening were related to concerns about confidentiality, most often in reference to women's family members and other women in their village. CONCLUSION: Integrated community-based cervical cancer and HIV testing would be highly acceptable to both women and CHWs.

7 August 2025 in Critical Care Explorations
Verified
Journal Article
Open access
AMAlex Mezei
Alex Mezei
DHDonatien Hitayezu
Donatien Hitayezu
TGTyler Gilman
Tyler Gilman
JBJeffrey Bone
Jeffrey Bone
CHCelestin Hategaka
Celestin Hategaka
TTTheogene Dr Twagirumugabe
Theogene Dr Twagirumugabe
IMPORTANCE: There is a large discrepancy between need and access to critical care in low- and middle-income countries. Little is known about what subgroups of patients are being prioritized for critical care. OBJECTIVES: The primary objective was to assess what clinical, demographic, and socioeconomic variables were associated with timely ICU admission. Secondary objectives included determining the rate of ICU admission among patients who met admission criteria, inpatient mortality, and length of stay. DESIGN: Prospective cohort study. SETTING AND PARTICIPANTS: All adult patients meeting ICU admission criteria at the University Teaching Hospital of Butare, Huye, Rwanda. MAIN OUTCOMES AND MEASURES: The primary outcome was the proportion of patients admitted to ICU within 24 hours of being identified as critically ill. A multivariable logistic regression model was used to assess whether clinical, demographic, or socioeconomic factors are associated with timely ICU admission. Secondary outcomes were the proportion of patients admitted to ICU at any time, inpatient mortality, and length of stay. RESULTS: Three hundred eighteen patients were enrolled between January 24, 2024, and June 3, 2024. Eighty-eight (27.7%) were admitted to ICU within 24 hours. Requiring ICU for postoperative recovery (odds ratio [OR], 8.21; 95% CI, 3.64–19.8), obstetric patients (OR, 2.43; 95% CI, 0.92–6.41), and ICU bed availability (OR, 1.26; 95% CI, 1.02–1.55) increased the odds of timely ICU admission in multivariable analysis. Socioeconomic status, gender, and social connections had minimal association with ICU admission, with wide CIs. The inpatient mortality rate was 44.0% and average length of stay was 14 days. CONCLUSIONS AND RELEVANCE: Obstetric and postoperative patients are prioritized for ICU admission. There is a large unmet need for critical care in Rwanda, and mortality among critically ill patients is high.